AbbVie Says Q2 2026 Includes $291M Bought IPR&D Expense, Impacting GAAP And Adj Diluted EPS By $0.17; Sees FY2026 Adj Diluted EPS At $13.91-$14.11 ; Sees Q2 2026 Adj Diluted EPS At $3.57-$3.61

Loading news article.

AbbVie Says Q2 2026 Includes $291M Bought IPR&D Expense, Impacting GAAP And Adj Diluted EPS By $0.17; Sees FY2026 Adj Diluted EPS At $13.91-$14.11 ; Sees Q2 2026 Adj Diluted EPS At $3.57-$3.61 | WAPE

AbbVie Says Q2 2026 Includes $291M Bought IPR&D Expense, Impacting GAAP And Adj Diluted EPS By $0.17; Sees FY2026 Adj Diluted EPS At $13.91-$14.11 ; Sees Q2 2026 Adj Diluted EPS At $3.57-$3.61

Article summary

Related companies

Comments —